[l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
D000109:Acetylcholine / Q000032:analysis; D001479:Basal Ganglia / Q000032:analysis; D002090:Butyrophenones / Q000494:pharmacology; D002819:Chorea / Q000188:drug therapy; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004298:Dopamine / Q000032:analysis / Q000494:pharmacology; D005116:Extrapyramidal Tracts / Q000187:drug effects; D006801:Humans; D008750:Methyldopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010640:Phenothiazines / Q000494:pharmacology; D012110:Reserpine / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000494:pharmacology*; D014966:Xanthenes / Q000494:pharmacology
D002090:Butyrophenones; D008996:Monoamine Oxidase Inhibitors; D010640:Phenothiazines; D014149:Tranquilizing Agents; D014966:Xanthenes; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D000109:Acetylcholine; D004298:Dopamine
l-Dopa-Behandlung des Parkinson-Syndroms und Wirkungsweise der Neurleptika.